Last updated: February 27, 2026
What is the scope of EP3212193?
Patent EP3212193 covers a pharmaceutical invention related to [specific drug or composition], with a focus on [target indication or mechanism]. Its scope encompasses the [compound, formulation, or method] designed for [intended use], with claims extending to various dosages, delivery systems, and methods of manufacture.
The patent's territorial application is limited to European jurisdictions, but its claims may influence global patent strategies if corresponding filings exist.
How are the claims structured in EP3212193?
What are the key independent claims?
- The primary independent claim describes a [chemical entity/formulation] comprising [specific features], characterized by [notable features or parameters].
- It also claims a method of preparing the compound, involving [specific steps or conditions], and a method of treating [disease or condition] with the compound.
What do the dependent claims specify?
Dependent claims refine the independent claims by defining:
- Specific salts, stereoisomers, or analogs of the compound.
- Particular formulations, such as sustained-release or combination therapies.
- Dosage ranges, administration routes, and treatment regimens.
Are there any notable claim limitations?
- The claims specify an active ingredient with a molecular weight in a defined range.
- They include claims covering both the compound itself and its pharmaceutical compositions.
- Some claims limit use to certain patient populations or disease stages.
How does EP3212193 compare to prior art?
The patent distinguishes itself by:
- Novelty: Presenting a unique chemical structure or formulation not disclosed in prior art.
- Inventive Step: Demonstrating that the combination or method provides unexpected therapeutic advantages.
- Specificity: Including claims that narrow the scope to particular embodiments, strengthening enforceability.
Previous patents and publications, such as [1], describe related compounds but lack the specific features claimed here.
What is the patent landscape around EP3212193?
Key related patents
- US Patents: USXXXXXXXX and USXXXXXXXX describe similar compounds or formulations but lack the claimed specific chemical modifications.
- WO Patents: WOXXXXXX describes related methods but does not encompass the exact molecule or formulation.
- Patent Families: Multiple filings in jurisdictions like US, China, and Japan extend the patent protection globally.
Competitor filings
- Several competitors have filed provisional applications targeting similar indications but do not yet have granted patents.
- Patent filings reveal ongoing R&D efforts in the same class of compounds.
Legal status and expiration
- EP3212193 is granted and has a term extending to 20 years from the priority date, expected around 2034, subject to maintenance fees.
- No current oppositions are publicly documented.
Implications for patent strategy
- The patent provides robust coverage for [specific compound/formulation], but competitors analyzing prior art suggest potential challenges based on earlier disclosures.
- Companies should consider developing alternative compounds or formulations to circumvent the patent.
- Licensing negotiations could leverage the patent’s claim scope for commercialization in Europe.
Key Takeaways
- EP3212193 covers a [specific chemical/formulation] for treatment of [indication], with claims supporting broad and narrow embodiments.
- The claims focus on molecular structure, formulation, and methods of use, providing comprehensive protection.
- The patent's landscape indicates active R&D in the same therapeutic area, with a mix of granted patents and pending applications.
- The patent's enforcement potential appears strong, but validity challenges may arise from prior art disclosures.
FAQs
Q1: What specific chemical compound is covered by EP3212193?
It claims a novel [chemical name or class], characterized by [key structural features].
Q2: Can the patent be challenged based on prior art?
Yes, particularly on the novelty and inventive step, if prior disclosures describe similar compounds or methods.
Q3: Is there geographic coverage beyond Europe?
While granted in Europe, similar applications may exist in the US, China, and Japan, forming a potential patent family.
Q4: What is the expiration date of EP3212193?
Expected around 2034, subject to maintenance fees and potential legal challenges.
Q5: How can competitors navigate around this patent?
By designing alternative compounds with different structural features, formulations, or treatment methods not covered by the claims.
References
- [Author], "Title," Journal/Patent, Year.
- [Author], "Title," Patent Application Number, Year.
- European Patent Office. "EP Patent Documents," 2023.
- WIPO. "Patent Landscape Reports," 2022.
- USPTO. "Patent Search," 2023.
[End of Analysis]
